

Annex Table 4. Baseline characteristics and results according to backbone.

Variables	XP 163 (27%)	CAPOX 158 (26%)	FOLFOX 86 (14%)	FP 81 (14%)	CarFU 30 (5%)
Age, median (range)	64 (29-82)	66 (36-86)	65 (31-85)	61 (22-87)	72 (33-84)
Sex, male	122 (74.8)	132 (83.5)	61 (70.9)	61 (75.3)	25 (83.3)
HER2					
3+	110 (67.5)	118 (74.7)	68 (79.1)	52 (64.2)	19 (63.3)
2+/FISH+	53 (32.5)	40 (25.4)	18 (20.9)	29 (35.8)	11 (36.7)
ECOG-PS					
0	50 (30.6)	44 (27.8)	14 (16.2)	19 (23.4)	0
1	98 (60.1)	95 (60.1)	50 (58.1)	55 (68.9)	20 (66.6)
2	15 (9.2)	19 (12.0)	22 (25.5)	7 (8.6)	10 (33.3)
Lauren subtype					
Intestinal	25 (15.3)	26 (16.4)	19 (22.0)	28 (34.5)	7 (23.3)
Diffuse or mixed	102 (62.5)	100 (63.2)	51 (59.3)	46 (56.7)	19 (63.3)
Indeterminate	36 (22.0)	32 (20.2)	16 (18.6)	7 (8.6)	4 (13.3)
Signet ring cells	15 (9.2)	12 (7.5)	14 (16.2)	17 (20.9)	7 (23.3)
Metastatic sites					
Ascitis	21 (12.8)	20 (12.6)	14 (16.2)	13 (16.0)	3 (10)
Peritoneal	43 (26.3)	47 (29.7)	27 (31.3)	27 (33.3)	11 (36.6)
Bone	11 (6.7)	18 (11.3)	11 (12.7)	7 (8.6)	2 (6.6)
Liver	96 (58.8)	97 (61.3)	48 (55.8)	34 (41.9)	16 (53.3)
Lung	35 (21.5)	40 (25.3)	19 (22.1)	21 (25.9)	5 (16.7)
Lymph nodes	88 (53.9)	85 (53.7)	40 (46.5)	46 (56.7)	17 (56.6)
Number of metastatic sites, >2	62 (38.0)	45 (28.4)	25 (29.0)	17 (20.9)	10 (33.3)
CEA, median (range)	15 (0-1887)	10 (0-12396)	8 (0-5384)	9 (1-8005)	6 (1-538)
Albumin					
Normal (>35 g/dl)	117 (71.7)	113 (71.5)	50 (58.1)	50 (61.7)	18 (60.0)
30-35	24 (14.7)	23 (14.5)	20 (23.2)	11 (13.5)	7 (23.3)
<30	12 (7.3)	8 (5.0)	9 (10.4)	9 (11.1)	8 (13.3)
No available	10 (6.1)	14 (8.8)	7 (8.1)	11 (13.5)	1 (3.3)
Surgery of primary cancer	42 (25.7)	28 (17.7)	23 (26.7)	14 (17.2)	6 (20.0)
Surgery of metastases	10 (6.1)	2 (1.2)	5 (5.8)	2 (2.4)	1 (3.3)

Abbreviations: FISH, fluorescence in situ hybridization; ECOG-PS, Eastern Cooperative Oncology Group performance status; XP, capecitabine-cisplatin; CAPOX, capecitabine-oxaliplatin; FOLFOX, fluorouracil-oxaliplatin; FP, fluorouracil-cisplatin; CarFU, carboplatin-fluorouracil.